By Scott Galloway, No Mercy/No Malice, @profgalloway
Audio Recording by George Hahn, Illustration and Charts by Shira Seri Levi
The hottest product in tech is Bluesky,...
The man often known as the "godfather of EVs" has a warning for automakers thinking of ditching electric vehicles for hybrids. Andy Palmer, a former Aston Martin CEO and Nissan exec, told Business Insider that delaying transitioning to EVs in favor of selling hybrids was a "fool's errand" and warned …
Wall Street’s main indexes all closed higher on Tuesday, with gains in megacap and growth stocks bolstering benchmarks in a truncated Christmas Eve session. Both the Dow Jones Industrial Average and Nasdaq Composite scored four straight sessions of gains, with the S&P 500 taking its winning streak …
Why A Santa Claus Rally May Be Coming
By Ilene (AI-assisted)
The traditional Santa Claus rally, which typically occurs during the last five trading days of...
The Biden administration said on Monday it launched an investigation into China's semiconductor sector, which officials claim threatens U.S. national …
Companies like OpenAI and Google are running out of the data used to train artificial intelligence systems. Can new methods continue years of rapid progress? Demis Hassabis, one of the most influential artificial intelligence experts in the world, has a warning for the rest of the tech industry: …
9 evergreen investor lessons from 2024
9 evergreen investor lessons from 2024
Plus a charted review of the macro crosscurrents
By Sam Ro, at TKer by Sam...
The federal government narrowly averted a year-end shutdown after an 11th-hour effort in the GOP-controlled House of Representatives to cobble a bill …
The weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by the U.S. Food and Drug Administration (FDA) to treat obstructive sleep apnea. In the trial that Lilly, the drug's manufacturer, submitted in April to the FDA, scientists …
Shares of Danish pharmaceutical giant Novo Nordisk plummeted roughly 20% on Friday after reporting results in a late-stage trial for its experimental …
New York CNN — The Dow plunged Wednesday on a disappointing outlook from the Federal Reserve. In the process, the blue-chip index extended its losing streak to 10 days — the longest such stretch since Gerald Ford was president. The Dow Jones Industrial Average ended the day down about 1,123 points, …
Most major media properties are tied to larger business interests that can benefit from government policy—or be harmed by it. Now that the election is over, Donald Trump has returned to one of his most cherished pastimes: filing nuisance lawsuits. Abusing the legal system was a key precept of …
The Federal Reserve announced a policy decision to cut interest rates by 0.25% on December 18. This decision was accompanied by Federal Open Market Committee member forecasts, which reflected expectations of fewer and slower additional Fed interest rate cuts through the end of 2025, 2026, and 2027 …
Here's what could happen to the S&P 500 in 2025. While most of Wall Street was skeptical that stocks could deliver back-to-back big years coming into …
Do we blame trade — or the fact that the United States addresses disruption very poorly? Americans are done with globalization. For the third time in a row, in November voters chose a president who promised to rein-in the thing. Indeed, in the past two elections there wasn’t a pro-globalization …
The weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by the U.S. Food and Drug Administration (FDA) to treat obstructive sleep apnea. In the trial that Lilly, the drug's manufacturer, submitted in April to the FDA, scientists …
Shares of Danish pharmaceutical giant Novo Nordisk plummeted roughly 20% on Friday after reporting results in a late-stage trial for its experimental …
The promising new treatment builds on research that went into developing COVID vaccines. Sign up for the Smarter Faster newsletter A weekly newsletter …